Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:1799
Name islet cell tumor
Definition A pancreatic cancer that is located_in the pancreatic islet cells.
Source DiseaseOntology.org
Alt Ids DOID:10165
Path disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer pancreatic cancer islet cell tumor

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
TSC1 inact mut N/A islet cell tumor not applicable detail...
TSC2 inact mut N/A islet cell tumor not applicable detail...
VHL inact mut N/A islet cell tumor not applicable detail...
VHL mutant Belzutifan islet cell tumor sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01465659 Phase Ib/II Pazopanib + Temozolomide Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery Completed USA 0
NCT01525082 Phase II Bevacizumab + Capecitabine + Temozolomide Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Completed USA 0
NCT01525550 FDA approved Sunitinib A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Completed USA | SVK | ROU | NOR | ITA | HUN | FRA | ESP | CZE | BEL | AUS 4
NCT01603004 Phase I Everolimus Sunitinib Potential Imaging and Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors Completed USA 0
NCT01784861 Phase Ib/II Everolimus + Vorolanib VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors Terminated USA 0
NCT02031536 Phase II Everolimus Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Terminated USA 0
NCT02101918 Phase II Aflibercept Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery Completed USA 0
NCT02315625 Phase II Everolimus Sunitinib Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery Terminated USA 0
NCT02611024 Phase Ib/II Irinotecan + Lurbinectedin Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors Recruiting USA | ITA | FRA | ESP | DEU | CHE 0
NCT02831179 Phase I Capecitabine + Temozolomide + Veliparib Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn 0
NCT03095274 Phase II Durvalumab Tremelimumab Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (DUNE) Completed ESP 0
NCT03351296 Phase II Bevacizumab + Capecitabine + Temozolomide Bevacizumab + Fluorouracil + Leucovorin + Streptozocin Two Chemotherapy Regimens Plus or Minus Bevacizumab (BETTER 2) Active, not recruiting FRA 0
NCT03736720 Phase II Fluorouracil + Leucovorin + Liposomal irinotecan Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin Active, not recruiting USA 0
NCT04086485 Phase Ib/II lutetium Lu 177 dotatate + Olaparib Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) Recruiting USA 0
NCT04609592 Phase I lutetium Lu 177 dotatate Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery Recruiting USA 0
NCT04893785 Phase II Cabozantinib + Temozolomide A Phase II Single Arm Interventional Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) (CABOTEM) Recruiting ITA 0
NCT04924075 Phase II Belzutifan Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET) (MK-6482-015) Recruiting USA | TUR | SWE | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CAN | AUS 4
NCT06472388 Phase II Everolimus Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors (EVENET) Recruiting BRA 0
NCT06663072 Phase I Fulvestrant + lutetium Lu 177 dotatate Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors Not yet recruiting USA 0